Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow Health Inc (HROW) is a leading developer of ophthalmic pharmaceuticals and non-intravenous sedation therapies, addressing critical needs in eyecare and procedural medicine. This dedicated news hub provides investors and healthcare professionals with timely access to official announcements and objective updates about the company's progress.
Our curated collection features earnings reports, regulatory milestones, and product development updates, offering a comprehensive view of HROW's strategic direction. Users will find essential information on FDA approvals, clinical trial results, and partnership announcements that shape the company's position in the pharmaceutical sector.
Key content categories include financial disclosures, research breakthroughs, and manufacturing updates related to compounded medications and sedation therapeutics. All materials are sourced from verified channels to ensure accuracy and relevance for decision-makers.
Bookmark this page for streamlined access to HROW's latest developments. Check back regularly for authoritative updates on innovations in ocular surface disease treatments and non-IV sedation solutions that demonstrate the company's commitment to advancing patient care.
Harrow (HROW) has appointed Amir H. Shojaei, PharmD, PhD as Chief Scientific Officer (CSO). Dr. Shojaei brings 28 years of life sciences experience, specializing in clinical development, regulatory affairs, and commercialization of biopharmaceutical products. He previously served as CSO at AsclepiX Therapeutics and held executive roles at TherOptix , Novartis, and Shire Pharmaceuticals.
Notable achievements include his instrumental role in the FDA approval of Xiidra® at Shire Pharmaceuticals in 2013, the first product approved for both signs and symptoms of dry eye disease. Dr. Shojaei succeeds Dennis E. Saadeh, who is retiring after nearly a decade of service to Harrow.
OSRX expressed disappointment with the jury verdict in ImprimisRx v. OSRX trademark infringement case. The jury found OSRX and Ocular Science guilty of willful trademark infringement and unfair competition, awarding $34.9 million in damages. OSRX disputes ImprimisRx's claims about trademark ownership of pharmaceutical abbreviations like 'Pred,' 'moxi,' 'dex' and 'brom.' The company argues that these are generic terms in ophthalmology, citing a survey showing 70% of eye care professionals consider them generic. OSRX plans to challenge the verdict, with pending legal issues to be decided in December, including laches, unclean hands, and fraud on the USPTO.
Harrow (HROW) announced a favorable jury verdict in a trademark infringement case where its subsidiary ImprimisRx sued OSRX, Inc. and Ocular Science, Inc. The eight-person jury unanimously found the defendants guilty of willful trademark infringement and unfair competition, awarding $34.9 million in damages. The verdict includes $20.4 million in punitive damages and $14.5 million in actual damages. The case was tried in the United States District Court for the Southern District of California, where the jury validated ImprimisRx's trademark estate and found the defendants acted with malice, fraud, or oppression.
Melt Pharmaceuticals announced positive Phase 3 topline results for MELT-300, a non-IV, non-opioid sublingual tablet for procedural sedation during cataract surgery. The study, involving over 530 patients across 13 U.S. clinical sites, demonstrated MELT-300's statistical superiority over both sublingual midazolam (P=0.009) and placebo (P<0.001). The tablet combines midazolam (3mg) and ketamine (50mg), dissolving in 3 seconds using Catalent's Zydis® technology. Patients receiving midazolam alone required nearly twice the rescue sedation compared to MELT-300 (P=0.003), while MELT-300 showed a favorable safety profile comparable to placebo.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, has announced its participation in three upcoming investor conferences. The company will attend the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, the BTIG 4th Annual Ophthalmology Day on December 2, 2024, and the Piper Sandler 36th Annual Healthcare Conference from December 3-5, 2024.
Management will conduct one-on-one meetings at all conferences. A Fireside Chat is scheduled for December 4, 2024, at 8:00 a.m. ET during the Piper Sandler conference, which will be the only event featuring an audio webcast available on Harrow's website.
Harrow (HROW) reported strong Q3 2024 results with revenues increasing 44% year-over-year to $49.3 million. The company posted a GAAP net loss of $(4.2) million and Adjusted EBITDA of $8.8 million. Key highlights include a 55% increase in VEVYE prescriptions over Q2 2024, 15% growth in IHEEZO customer unit demand, and operating cash flow of $3 million. The company maintained strong cash position with $72.6 million in cash and equivalents. Despite Q3 seasonal challenges, management expects Q4 revenue to meaningfully exceed 2024 guidance, driven by positive demand trends for VEVYE, IHEEZO, and TRIESENCE products.
Harrow (HROW) announced a new initiative to improve access and affordability of its ophthalmic pharmaceutical products through two main strategies. First, the company is implementing price reductions for several products, starting with VIGAMOX® and MAXIDEX®. Second, Harrow established a partnership with GoodRx to provide discounted pricing for seven products including FLAREX®, ILEVRO®, MAXIDEX®, TOBRADEX® ST, VEVYE®, VIGAMOX®, and ZERVIATE® through GoodRx's platform, particularly benefiting uninsured and underinsured patients.
Harrow (HROW) has secured significant market access for VEVYE in the 2025 Medicare Part D Prescription Drug Program. Starting January 1, 2025, VEVYE will be included in formularies managed by Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark, reaching over 25 million Medicare Part D beneficiaries. The drug has achieved coverage across 100% of U.S. Medicaid programs and 60% of commercial insurance coverage. This expansion particularly benefits older adults among the 67 million Medicare beneficiaries, including 54 million with Part D coverage, who are at increased risk for chronic dry eye disease (DED).
Harrow (HROW) has announced a nationwide launch of a digital patient access solution in partnership with Asembia, aiming to expand access to Harrow's ophthalmic branded products. The collaboration leverages ASPN Pharmacies, Asembia's non-dispensing pharmacy, to streamline prescription processes and improve medication accessibility and affordability. The service includes benefits verification, prior authorization, co-pay support, and patient assistance program eligibility. Healthcare providers can order through their EHR/EMR platforms or the ASPN provider portal, which allows multiple Harrow products to be ordered simultaneously.
Harrow (Nasdaq: HROW), a North American eyecare pharmaceutical company, has scheduled its third quarter 2024 financial results announcement for November 13, 2024, after market close. The company will publish its quarterly Letter to Stockholders on its website and host a conference call with a business update on November 14, 2024, at 8:00 a.m. Eastern Time. Interested participants can join via webcast through Harrow's website or by telephone after registering in advance.
